## Conflict of interest (COI) register

### National Heart Foundation of Australia (NHFA) and Cardiac Society of Australia and New Zealand (CSANZ)

**Australian Clinical Guidelines for the management of Atrial Fibrillation working group (WG) 2018**

<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
</table>
| John Amerena                  | Director, Geelong Cardiology Research Unit
University Hospital Geelong         | **Personal, low level pecuniary interest:**
Advisory Board Member: Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Pfizer
Sponsored lectures; Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Pfizer
Sponsored travel; Boehringer Ingelheim, Bayer and Bristol-Myers Squibb, Pfizer - sponsorship to attend European Society of Cardiology and APHRS |
| John Attia                    | Professor of Medicine and Clinical Epidemiology, University of Newcastle                     | No interests declared                                                                                                                                                                                                |
| Beata Bajorek                 | Academic Pharmacist
Graduate School of Health, University of Technology Sydney & Department of Pharmacy  | **Personal, non-pecuniary interests:**
Professional: Member - Committees of Special Practice (Cardiology, Geriatrics, Medication Safety), Society of Hospital Pharmacists of Australia (SHPA); Assistant Editor, Journal of Pharmacy Practice and Research (SHPA); Member, Stroke Guidelines Working Group, National Stroke Foundation (2009-11, 2016-17)
Academic: supervisor of research projects in AF, stroke, anticoagulation

**Personal, low-level pecuniary interests:**
Professional: Paid columnist - Retail Pharmacy Gazette (professional development articles on various topics)
Honorariums/travel support for presentations and/or expert commentary relating to AF, anticoagulation, adherence to cardiovascular medications (Meditrax, Pharmaceutical Society of Australia, Pharmacy Guild, National Prescribing Service, National Stroke Foundation)
Research funding from: NHMRC and National Heart Foundation of Australia (Vanguard Grant; Project Grant; Funding Tender for “Improving adherence in cardiovascular care - A toolkit for health professionals” - Heart Foundation Pharmaceutical Roundtable)

**Personal, high-level pecuniary interests:**
Professional: Paid columnist - Retail Pharmacy Gazette (monthly professional development articles on various topics) |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Brieger</td>
<td>Head of Coronary Care, Concord Hospital</td>
<td><strong>Personal, low level pecuniary interests:</strong> Consultancy for: Boehringer Ingelheim, Novartis, Astra Zeneca, Bayer, Eli Lilly &lt;br&gt;Travel support from: Boehringer Ingelheim &lt;br&gt;<strong>Non-personal, low level pecuniary interests:</strong> Research funding: Astra Zeneca, Sanofi Aventis</td>
</tr>
<tr>
<td>Kim Chan</td>
<td>Staff Specialist Cardiologist Royal Prince Alfred Hospital</td>
<td><strong>Personal, low-level pecuniary interests:</strong> Travel support from Abbott, Medtronic</td>
</tr>
<tr>
<td>Cia Connell</td>
<td>Clinical Policy Advisor, Heart Foundation</td>
<td><strong>Personal, non-pecuniary interests:</strong> Academic: supervisor of research projects in AF (post-operative AF; use of dual antiplatelet therapy in combination with oral anticoagulants following percutaneous coronary intervention) &lt;br&gt;Academic: author of Therapeutic Guidelines Cardiovascular, Version 7 &lt;br&gt;Professional: Member of cardiology leadership committee for Society of Hospital Pharmacists of Australia (SHPA) Committee of Special Practice &lt;br&gt;<strong>Personal, low-level pecuniary interests:</strong> Money paid to me by Society of Hospital Pharmacists of Australia to give presentations about atrial fibrillation (not related to guideline) (2018) &lt;br&gt;Money paid to me from Pharmaceutical Society of Australia to write an article for the <em>Australian Pharmacist</em> about aspirin use (June 2017)</td>
</tr>
<tr>
<td>Caleb Ferguson</td>
<td>Senior Research Fellow Western Sydney University &amp; Western Sydney Local Health District</td>
<td><strong>Non-personal, non-pecuniary interests:</strong> Board Director of; Australian Cardiovascular Nursing College &lt;br&gt;Executive Member: Cardiac Society of Australia &amp; New Zealand – Cardiovascular Nursing Council &lt;br&gt;Academic; Nursing co-chair executive writing group – Stroke Foundation (2017) Guidelines for Clinical Management. &lt;br&gt;<strong>Non-personal, low-level pecuniary interest:</strong> Grant received from the Stroke Foundation – Future Leader Award &lt;br&gt;<strong>Non-personal, high-level pecuniary interest:</strong> Grant received for research at University of Technology Sydney &lt;br&gt;<strong>Personal, low-level pecuniary interests:</strong> Honorarium for teaching; Pfizer &lt;br&gt;Payment for manuscript writing and review for Elsevier and Lippincott Williams &amp; Wilkins</td>
</tr>
<tr>
<td>Member</td>
<td>Employment/Current position</td>
<td>Declared interests</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Ben Freedman  | Deputy Director Research Strategy, Heart Research Institute/Charles Perkins Centre, University of Sydney Honoray VMO and Professor of cardiology, Concord Hospital Dept of Cardiology, Concord Clinical School, Faculty of Medicine and health University of Sydney | **Personal, low level pecuniary interests:** Consultancy Boards; Bayer, Bristol-Myers Squibb/Pfizer regarding New Oral Anticoagulant. None since Oct 2016
Sponsored lectures; Bristol-Myers Squibb/Pfizer, Bayer, regarding Atrial Fibrillation screening. None at pharma meetings other than official meetings of professional bodies (ESC, RACGP, HRS) since Oct 2016
Payment for manuscript; Bristol-Myers Squibb/Pfizer article of persistence of New Oral Anticoagulants
**Non-personal, low-level pecuniary interests:**
Research grant for AF screening (investigator-initiated grant to institution for project part funded by Heart Foundation Vanguard and Heart Foundation NSW CVRN grants) Pfizer |
| Tanya Hall    | CEO, Hearts4Hearts                                                                           | **Non-personal, high-level pecuniary interests:**
2017 Grants paid to my institution at Hearts4Heart for the running of the organisation and projects for which I am responsible for from Medtronic, Boston Scientific, Biotronik and St Jude
2018 Grants paid to my institution Hearts4Heart for the running of the organisation which I am responsible for from, Boston Scientific, Biotronik and St Jude
**Non-personal, low-level pecuniary interests:**
2017 grant paid to my institution at hearts4heart for projects for which I am responsible for from Bristol-Myers Squibb and Boehringer Ingelheim
2018 Grant paid to my institution at hearts4heart for which I am responsible for from Bristol-Myers Squibb
**Non-pecuniary Interest:**
2017/2018 Member of the Australasian Cardiac Outcomes Registry, Cardiac Devices and Procedures registries |
| Haris Haqqani | Senior Cardiologist and Electrophysiologist, The Prince Charles Hospital                     | **Personal, Low-level pecuniary interests:**
- Advisory boards for pharmaceutical industry; Boston scientific Consultancy; Boston scientific
- Sponsored lectures; Boston scientific, Medtronic, St Jude, Abbott, Astra Zeneca
**Non-personal, low-level pecuniary interest:**
Grant received; Biosense Webster |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
</table>
| Jeroen Hendriks        | Derek Frewin Lectureship Royal Adelaide Hospital                  | **Personal, non-pecuniary interests:**  
Board Director of the Australasian Cardiovascular Nursing College; Vice-President of the Australian Cardiovascular Health and Rehabilitation Association (SA/NT).  
Supported by the Derek Frewin Lectureship – University of Adelaide  
Supported by a Post-Doctoral Fellowship – National Heart Foundation of Australia  
**Non-personal, low level pecuniary interests:**  
The University of Adelaide has received consulting and lecture fees on my behalf from: Medtronic, Pfizer/BMS |
| Charlotte Hespe        | Head, General Practice and Primary Care Research School of Medicine, | **Personal, low level pecuniary interests:**  
GP Advisory boards for pharmaceutical industry; Glaxo Smith Kline, Sanofi  
Board Directorship of Central and Eastern Sydney PHN, RACGP  
GP Advisory panel ACI, NSW Health  
Clinical Reference Lead Digital Health Authority  
Member Post PBS review panel for Ezetimide / Pulmonary Hypertension  
Member Professional Services Review Panel  
**Non-personal, low level pecuniary interests:**  
Recipient Bupa Health Foundation Health Award  
Research grants NHMRC, AMGEN, Sanofi |
| Joe Hung               | Honorary Senior Research Fellow, UWA  
Harry Perkins Institute of Medical Research                         | **Personal, low-level pecuniary interests:**  
Travel and accommodation expenses to attend the Cardiovascular Alliance meeting sponsored by Bayer in 2016; travel and accommodation expenses to attend the Cardiovascular forum in 2017 sponsored by Bristol-Myers Squibb and Pfizer; honorarium and travel and accommodation expenses to attend a PBS/MBS Real World Evidence Advisory Board meeting in 2018 sponsored by Bayer Australia Ltd |
| Jonathan M. Kalman     | Director of Cardiac Electrophysiology Royal Melbourne Hospital    | **Non-personal, low-level pecuniary interests:**  
Advisory boards for pharmaceutical industry; Biosense Webster, Boston Scientific  
Grant support received from Medtronic, Abbott, Biosense Webster, Boston Scientific  
Sponsored lectures; Medtronic, Abbott, Biosense Webster  
**Personal, low-level pecuniary interest:**  
Support for meeting expenses; Abbott  
Practitioner Fellowship of the NHMRC. |
<table>
<thead>
<tr>
<th>Member</th>
<th>Employment/Current position</th>
<th>Declared interests</th>
</tr>
</thead>
</table>
| Prashanthan Sanders    | Director, Cardiac Electrophysiology & Pacing, Royal Adelaide Hospital; Director, Centre for Heart Rhythm Disorders, University of Adelaide; Group Leader, Heart Rhythm, South Australian Health and Medical Research Institute | Non-personal, low level pecuniary interests:  
Advisory board for pharmaceutical industry; Biosense-Webster, Medtronic, Boston Scientific, Abbott, CathRx  
The University of Adelaide has received consulting and lecture fees on my behalf from: Pfizer, Boston Scientific, Biosense Webster, Medtronic and Abbott.  
The University of Adelaide has received research funding on my behalf from: Abbott, Medtronic Boston Scientific, Biotronik and LivaNova.  
Grants received from National Heart Foundation of Australia and NHMRC  
Travel support from: Bayer and Pfizer |
| John Worthington       | Liverpool Health Service, Royal Prince Alfred Hospital                                      | Personal, non-pecuniary interests:  
Personal, low-level pecuniary interest:  
Paid member of AVANT medical expert committee, with some topics relevant to stroke prevention.  
Personal, high-level pecuniary interests:  
Consultancy for NSW Agency of Clinical Innovation as Clinical-lead on Stroke Clinical Audit Project (SCAP) addressing unwarranted clinical variation in NSW. Completed 2017. South Western Sydney LHD research funding and salary as Director Stroke and Health Services Research Unit in SWS (ended Feb 2017).  
Non-personal, low-level pecuniary interests:  
Past grants from NHMRC, BUPA and UNSW |
| Tristan Yan            | Cardiothoracic surgeon Royal Prince Alfred Hospital                                         | No interests declared                                                                                                                                                                                                 |
| Nicholas Zwar          | General Practitioner Dean of Medicine, University of Wollongong                            | Personal, non-pecuniary interests:  
Chair of Editorial Committee for 9th Edition of RACGP Guidelines for Preventive Activities in General Practice  
Chair of Content Advisory Group RACGP smoking cessation guidelines;  
Member COPD-X Evaluation Committee, Lung Foundation Australia,  
Grants received from Heart Foundation of Australia and NHMRC |